| Date:Apr.               | . 12 <sup>th</sup> , 2023  |
|-------------------------|--|
| Your Name:              | Xiangwen Li  |
| <b>Manuscript Title</b> | e: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation with |
| QCT-derived bo          | ne mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal       |
| women                   |  |
| Manuscript nun          | nber (if known):QIMS-22-1247-R3  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |
|---|---|---|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |
|   | Time frame: past 36 months  |   |   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |
| 3 | Royalties or licenses   | XNone   |   |  |

| 4   | Consulting fees                                 | XNone  |  |
|---|---|--------|--|
|   |   |        |  |
|   |   |        |  |
| 5   | Payment or honoraria for                        | XNone  |  |
|   | lectures, presentations,                        |        |  |
|   | speakers bureaus,                               |        |  |
|   | manuscript writing or educational events        |        |  |
| 6   | Payment for expert                              | X None |  |
|   | testimony                                       | XNONE  |  |
|   | ,   |        |  |
| 7   | Support for attending                           | XNone  |  |
|   | meetings and/or travel                          |        |  |
|   |   |        |  |
|   |   |        |  |
|   |   |        |  |
| 8   | Patents planned, issued or                      | XNone  |  |
|   | pending   |        |  |
|   |   |        |  |
| 9   | Participation on a Data                         | XNone  |  |
|   | Safety Monitoring Board or                      |        |  |
|   | Advisory Board                                  |        |  |
| 10  | Leadership or fiduciary role                    | XNone  |  |
|   | in other board, society,                        |        |  |
|   | committee or advocacy                           |        |  |
|   | group, paid or unpaid                           |        |  |
| 11  | Stock or stock options                          | XNone  |  |
|   |   |        |  |
| 42  | Descipt of any 1                                | V None |  |
| 12  | Receipt of equipment, materials, drugs, medical | X_None |  |
|   | writing, gifts or other                         |        |  |
|   | services  |        |  |
| 12  |   | V None |  |
| 13  | Other financial or non-<br>financial interests  | XNone  |  |
|   | illiandal illerests                             |        |  |
|   |   |        |  |
| Please summarize the above conflict of interest in the following box: |   |        |  |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date:     | _Apr. 12 <sup>th</sup> , 2023   |
|-----------|---|
| Your Nam  | e:Yiwen Hu  |
| Manuscri  | ot Title: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation witl |
| QCT-deriv | ed bone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal         |
| women     |   |
| Manuscri  | ot number (if known):QIMS-22-1247-R3  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |
|---|---|---|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |
|   | Time frame: past 36 months  |   |   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |
| 3 | Royalties or licenses   | XNone   |   |  |

| 4   | Consulting fees                                 | XNone  |  |
|---|---|--------|--|
|   |   |        |  |
|   |   |        |  |
| 5   | Payment or honoraria for                        | XNone  |  |
|   | lectures, presentations,                        |        |  |
|   | speakers bureaus,                               |        |  |
|   | manuscript writing or educational events        |        |  |
| 6   | Payment for expert                              | X None |  |
|   | testimony                                       | XNONE  |  |
|   | ,   |        |  |
| 7   | Support for attending                           | XNone  |  |
|   | meetings and/or travel                          |        |  |
|   |   |        |  |
|   |   |        |  |
|   |   |        |  |
| 8   | Patents planned, issued or                      | XNone  |  |
|   | pending   |        |  |
|   |   |        |  |
| 9   | Participation on a Data                         | XNone  |  |
|   | Safety Monitoring Board or                      |        |  |
|   | Advisory Board                                  |        |  |
| 10  | Leadership or fiduciary role                    | XNone  |  |
|   | in other board, society,                        |        |  |
|   | committee or advocacy                           |        |  |
|   | group, paid or unpaid                           |        |  |
| 11  | Stock or stock options                          | XNone  |  |
|   |   |        |  |
| 42  | Descipt of any 1                                | V None |  |
| 12  | Receipt of equipment, materials, drugs, medical | X_None |  |
|   | writing, gifts or other                         |        |  |
|   | services  |        |  |
| 12  |   | V None |  |
| 13  | Other financial or non-<br>financial interests  | XNone  |  |
|   | illiandal illerests                             |        |  |
|   |   |        |  |
| Please summarize the above conflict of interest in the following box: |   |        |  |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date:Apr. 12 <sup>th</sup> , 2023 |   |
|-----------------------------------|---|
| Your Name:Yuxue Xie               |   |
| Manuscript Title: T2*-corrected   | Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation with |
| QCT-derived bone mineral densi    | y (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal       |
| women                             |   |
| Manuscript number (if known):_    | QIMS-22-1247-R3   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |
|---|---|---|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |
|   | Time frame: past 36 months  |   |   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |
| 3 | Royalties or licenses   | XNone   |   |  |

| 4   | Consulting fees                                 | XNone  |  |
|---|---|--------|--|
|   |   |        |  |
|   |   |        |  |
| 5   | Payment or honoraria for                        | XNone  |  |
|   | lectures, presentations,                        |        |  |
|   | speakers bureaus,                               |        |  |
|   | manuscript writing or educational events        |        |  |
| 6   | Payment for expert                              | X None |  |
|   | testimony                                       | XNONE  |  |
|   | ,   |        |  |
| 7   | Support for attending                           | XNone  |  |
|   | meetings and/or travel                          |        |  |
|   |   |        |  |
|   |   |        |  |
|   |   |        |  |
| 8   | Patents planned, issued or                      | XNone  |  |
|   | pending   |        |  |
|   |   |        |  |
| 9   | Participation on a Data                         | XNone  |  |
|   | Safety Monitoring Board or                      |        |  |
|   | Advisory Board                                  |        |  |
| 10  | Leadership or fiduciary role                    | XNone  |  |
|   | in other board, society,                        |        |  |
|   | committee or advocacy                           |        |  |
|   | group, paid or unpaid                           |        |  |
| 11  | Stock or stock options                          | XNone  |  |
|   |   |        |  |
| 42  | Descipt of any 1                                | V None |  |
| 12  | Receipt of equipment, materials, drugs, medical | X_None |  |
|   | writing, gifts or other                         |        |  |
|   | services  |        |  |
| 12  |   | V None |  |
| 13  | Other financial or non-<br>financial interests  | XNone  |  |
|   | illiandal illerests                             |        |  |
|   |   |        |  |
| Please summarize the above conflict of interest in the following box: |   |        |  |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date: Apr. 12 <sup>th</sup> , 2023  |
|---|
| Your Name:Rong Lu   |
| Manuscript Title: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation with |
| QCT-derived bone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal        |
| women   |
| Manuscript number (if known):QIMS-22-1247-R3  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |  |
|---|---|---|---|--|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |  |
|   | Time frame: past 36 months  |   |   |  |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |  |
| 3 | Royalties or licenses   | XNone   |   |  |  |

| 4    | Consulting fees                                 | XNone                        |             |
|------|---|------------------------------|-------------|
|      |   |                              |             |
|      |   |                              |             |
| 5    | Payment or honoraria for                        | XNone                        |             |
|      | lectures, presentations,                        |                              |             |
|      | speakers bureaus,                               |                              |             |
|      | manuscript writing or educational events        |                              |             |
| 6    | Payment for expert                              | X None                       |             |
|      | testimony                                       | XNONE                        |             |
|      | ,   |                              |             |
| 7    | Support for attending                           | XNone                        |             |
|      | meetings and/or travel                          |                              |             |
|      |   |                              |             |
|      |   |                              |             |
|      |   |                              |             |
| 8    | Patents planned, issued or                      | XNone                        |             |
|      | pending   |                              |             |
|      |   |                              |             |
| 9    | Participation on a Data                         | XNone                        |             |
|      | Safety Monitoring Board or                      |                              |             |
|      | Advisory Board                                  |                              |             |
| 10   | Leadership or fiduciary role                    | XNone                        |             |
|      | in other board, society,                        |                              |             |
|      | committee or advocacy                           |                              |             |
|      | group, paid or unpaid                           |                              |             |
| 11   | Stock or stock options                          | XNone                        |             |
|      |   |                              |             |
| 42   | Descipt of any 1                                | V None                       |             |
| 12   | Receipt of equipment, materials, drugs, medical | X_None                       |             |
|      | writing, gifts or other                         |                              |             |
|      | services  |                              |             |
| 12   |   | V None                       |             |
| 13   | Other financial or non-<br>financial interests  | XNone                        |             |
|      | illiandal illerests                             |                              |             |
|      |   |                              |             |
| Plea | se summarize the above co                       | nflict of interest in the fo | lowing box: |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date: Apr. 12 <sup>th</sup> , 2023  |
|---|
| Your Name:Qing Li   |
| Manuscript Title: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation with |
| QCT-derived bone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal        |
| women   |
| Manuscript number (if known):QIMS-22-1247-R3  |
|   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |  |
|---|---|---|---|--|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |  |
|   | Time frame: past 36 months  |   |   |  |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |  |
| 3 | Royalties or licenses   | XNone   |   |  |  |

| 4    | Consulting fees                                 | XNone                        |             |
|------|---|------------------------------|-------------|
|      |   |                              |             |
|      |   |                              |             |
| 5    | Payment or honoraria for                        | XNone                        |             |
|      | lectures, presentations,                        |                              |             |
|      | speakers bureaus,                               |                              |             |
|      | manuscript writing or educational events        |                              |             |
| 6    | Payment for expert                              | X None                       |             |
|      | testimony                                       | XNONE                        |             |
|      | ,   |                              |             |
| 7    | Support for attending                           | XNone                        |             |
|      | meetings and/or travel                          |                              |             |
|      |   |                              |             |
|      |   |                              |             |
|      |   |                              |             |
| 8    | Patents planned, issued or                      | XNone                        |             |
|      | pending   |                              |             |
|      |   |                              |             |
| 9    | Participation on a Data                         | XNone                        |             |
|      | Safety Monitoring Board or                      |                              |             |
|      | Advisory Board                                  |                              |             |
| 10   | Leadership or fiduciary role                    | XNone                        |             |
|      | in other board, society,                        |                              |             |
|      | committee or advocacy                           |                              |             |
|      | group, paid or unpaid                           |                              |             |
| 11   | Stock or stock options                          | XNone                        |             |
|      |   |                              |             |
| 42   | Descipt of any 1                                | V None                       |             |
| 12   | Receipt of equipment, materials, drugs, medical | X_None                       |             |
|      | writing, gifts or other                         |                              |             |
|      | services  |                              |             |
| 12   |   | V None                       |             |
| 13   | Other financial or non-<br>financial interests  | XNone                        |             |
|      | illiandal illerests                             |                              |             |
|      |   |                              |             |
| Plea | se summarize the above co                       | nflict of interest in the fo | lowing box: |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date:            | _ Apr. 12 <sup>th</sup> , 2023   |
|------------------|--|
| <b>Your Name</b> | : Robert Grimm   |
| Manuscript       | t Title: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation with |
| QCT-derive       | d bone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal         |
| women            |  |
| Manuscript       | t number (if known):QIMS-22-1247-R3  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |
|---|---|---|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |
|   | Time frame: past 36 months  |   |   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |
| 3 | Royalties or licenses   | XNone   |   |  |

| 4    | Consulting fees                                 | XNone                        |             |
|------|---|------------------------------|-------------|
|      |   |                              |             |
|      |   |                              |             |
| 5    | Payment or honoraria for                        | XNone                        |             |
|      | lectures, presentations,                        |                              |             |
|      | speakers bureaus,                               |                              |             |
|      | manuscript writing or educational events        |                              |             |
| 6    | Payment for expert                              | X None                       |             |
|      | testimony                                       | XNONE                        |             |
|      | ,   |                              |             |
| 7    | Support for attending                           | XNone                        |             |
|      | meetings and/or travel                          |                              |             |
|      |   |                              |             |
|      |   |                              |             |
|      |   |                              |             |
| 8    | Patents planned, issued or                      | XNone                        |             |
|      | pending   |                              |             |
|      |   |                              |             |
| 9    | Participation on a Data                         | XNone                        |             |
|      | Safety Monitoring Board or                      |                              |             |
|      | Advisory Board                                  |                              |             |
| 10   | Leadership or fiduciary role                    | XNone                        |             |
|      | in other board, society,                        |                              |             |
|      | committee or advocacy                           |                              |             |
|      | group, paid or unpaid                           |                              |             |
| 11   | Stock or stock options                          | XNone                        |             |
|      |   |                              |             |
| 42   | Descipt of any 1                                | V None                       |             |
| 12   | Receipt of equipment, materials, drugs, medical | X_None                       |             |
|      | writing, gifts or other                         |                              |             |
|      | services  |                              |             |
| 12   |   | V None                       |             |
| 13   | Other financial or non-<br>financial interests  | XNone                        |             |
|      | illiandal illerests                             |                              |             |
|      |   |                              |             |
| Plea | se summarize the above co                       | nflict of interest in the fo | lowing box: |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date:            | Apr. 12 <sup>th</sup> , 2023   |        |
|------------------|--|--------|
| <b>Your Name</b> | Hongyue Tao  |        |
| Manuscript       | Title: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlatio | n with |
| QCT-derive       | d bone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopau    | ısal   |
| women            |  |        |
| Manuscript       | number (if known):QIMS-22-1247-R3  |        |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |
|---|---|---|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |
|   | Time frame: past 36 months  |   |   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |
| 3 | Royalties or licenses   | XNone   |   |  |

| 4    | Consulting fees   | XNone  |  |  |
|------|---|--------|--|--|
|      |   |        |  |  |
|      |   |        |  |  |
| 5    | Payment or honoraria for  | XNone  |  |  |
|      | lectures, presentations,  |        |  |  |
|      | speakers bureaus,   |        |  |  |
|      | manuscript writing or educational events                              |        |  |  |
| 6    | Payment for expert  | X None |  |  |
| U    | testimony   |        |  |  |
|      | testimon,   |        |  |  |
| 7    | Support for attending   | X None |  |  |
|      | meetings and/or travel  |        |  |  |
|      | _   |        |  |  |
|      |   |        |  |  |
|      |   |        |  |  |
| 8    | Patents planned, issued or  | X None |  |  |
|      | pending   |        |  |  |
|      |   |        |  |  |
| 9    | Participation on a Data   | X None |  |  |
|      | Safety Monitoring Board or  |        |  |  |
|      | Advisory Board  |        |  |  |
| 10   | Leadership or fiduciary role  | XNone  |  |  |
|      | in other board, society,  |        |  |  |
|      | committee or advocacy   |        |  |  |
|      | group, paid or unpaid   |        |  |  |
| 11   | Stock or stock options  | XNone  |  |  |
|      |   |        |  |  |
|      |   |        |  |  |
| 12   | Receipt of equipment,   | X_None |  |  |
|      | materials, drugs, medical   |        |  |  |
|      | writing, gifts or other   |        |  |  |
|      | services  |        |  |  |
| 13   | Other financial or non-   | XNone  |  |  |
|      | financial interests   |        |  |  |
|      |   |        |  |  |
| Plea | Please summarize the above conflict of interest in the following box: |        |  |  |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |

| Date: A             | pr. 12 <sup>th</sup> , 2023   |
|---------------------|---|
| Your Name:_         | Shuang Chen   |
| <b>Manuscript T</b> | itle: T2*-corrected Q-Dixon and reduced-FOV diffusion kurtosis imaging (DKI) parameters: Correlation with |
| <b>QCT-derived</b>  | oone mineral density (BMD) and ability to identify abnormal BMD and osteoporosis in postmenopausal        |
| women               |   |
| Manuscript n        | umber (if known):QIMS-22-1247-R3  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |  |
|---|---|---|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | National Natural Science<br>Foundation of China (Nos.<br>82271968 and 82171911).  |   |  |
|   | Time frame: past 36 months  |   |   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone   |   |  |
| 3 | Royalties or licenses   | XNone   |   |  |

| 4    | Consulting fees   | XNone  |  |  |
|------|---|--------|--|--|
|      |   |        |  |  |
|      |   |        |  |  |
| 5    | Payment or honoraria for  | XNone  |  |  |
|      | lectures, presentations,  |        |  |  |
|      | speakers bureaus,   |        |  |  |
|      | manuscript writing or educational events                              |        |  |  |
| 6    | Payment for expert  | X None |  |  |
| U    | testimony   |        |  |  |
|      | testimon,   |        |  |  |
| 7    | Support for attending   | X None |  |  |
|      | meetings and/or travel  |        |  |  |
|      | _   |        |  |  |
|      |   |        |  |  |
|      |   |        |  |  |
| 8    | Patents planned, issued or  | X None |  |  |
|      | pending   |        |  |  |
|      |   |        |  |  |
| 9    | Participation on a Data   | X None |  |  |
|      | Safety Monitoring Board or  |        |  |  |
|      | Advisory Board  |        |  |  |
| 10   | Leadership or fiduciary role  | XNone  |  |  |
|      | in other board, society,  |        |  |  |
|      | committee or advocacy   |        |  |  |
|      | group, paid or unpaid   |        |  |  |
| 11   | Stock or stock options  | XNone  |  |  |
|      |   |        |  |  |
|      |   |        |  |  |
| 12   | Receipt of equipment,   | X_None |  |  |
|      | materials, drugs, medical   |        |  |  |
|      | writing, gifts or other   |        |  |  |
|      | services  |        |  |  |
| 13   | Other financial or non-   | XNone  |  |  |
|      | financial interests   |        |  |  |
|      |   |        |  |  |
| Plea | Please summarize the above conflict of interest in the following box: |        |  |  |

| This work was supported by the National Natural Science Foundation of China (Nos. 82271968 and 82171911). |  |
|---|--|
|   |  |